Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Recruiting now · Phase 1
Conditions studied: Ovarian Cancer
In brief
This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with topotecan.
Key facts
- Study ID
- NCT06930755
- Run by
- Nerviano Medical Sciences
- People needed
- 24
- Starts
- 2026-05-13
- Expected to finish
- 2027-09-26
- Last updated by the study team
- 2026-05-28
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- OSF Saint Francis Medical Center — Peoria, Illinois, United States (enrolling)
- Washington University School of Medicine in St. Louis — St Louis, Missouri, United States (enrolling)
- Penn Medicine - Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania, United States (enrolling)
- Tennessee Oncology — Nashville, Tennessee, United States (enrolling)
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.